Fingolimod (Gilenya) eligibility extended in Scotland

The Scottish Medicines Consortium (SMC), which issues guidance on whether treatments should be funded by NHS Scotland, has announced that fingolimod can now be prescribed as a second line treatment for people who are continuing to have relapses despite taking any one of the disease modifying treatments.
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news